drugset / Trial / NCT07787429
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Phase 2
Recruiting
40 enrolled
Anna Raciborska
Maria Sklodowska-Curie National Research Institute of Oncology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Prospective, open, interventional, randomized, non-commercial trial
Timeline
- Start
- 2026-04-01
- Primary completion
- 2033-07-31
- Completion
- 2033-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mifamurtide | Other / unclassified | — | Intravenous |
| Subject | Sorafenib | Small molecule | — | — |